Johnson's hepatitis C drug approved by EU

The Johnson & Johnson (JNJ) Hepatitis C New Drug has been approved by the European Union in combination with other drugs for the treatment of Hepatitis C virus (HCV) genotypes 1 and 4 in adults with chronic hepatitis C (CHC). The drug will provide a new triple therapy for European patients and will also provide the first ever 12-week treatment option without interferon and independent of ribavirin and other drugs.

The approval of OLYSIO is based on data from phase II COSMOS, three key phase III QUEST-1, QUEST-2, and PROMISE. Hepatitis C (HCV) is a blood-borne infectious liver disease that can cause significant damage to the liver if left untreated.

About OLYSIO (simeprevir):

Is a new generation of NS3/4A protease inhibitor, a once-a-day oral drug developed jointly by Medivir and Janssen for the treatment of compensated liver disease in adult patients with chronic hepatitis C, including various phases of liver fiber The principle of its work is to inhibit the replication of HCV in liver cells by blocking proteases.

Simeprevir was approved by Japan (Sovriad in Japan) and FDA approval in September and November 2013, respectively, in combination with pegylated interferon and ribavirin for chronic genotype-1 Treatment of people infected with hepatitis C virus (HCV).

Simeprevir is a new direct-acting antiviral drug and is also a second-generation protease inhibitor administered as a combination of simeprevir+pegylated interferon plus ribavirin for 12 weeks followed by pegylated interferon + Ribavirin for 12 weeks or 36 weeks.